Alzheimer s & Dementia · 2023 · 32 citations · 34 references
MedicineNeurosciencePsychologyAnalytical ChemistryCognitive NeuroscienceNeuropsychologyCognitive Function AssessmentCognitive ImpairmentNeurocognitive AssessmentNeurocognitive DisordersNeuropsychological AssessmentVolatile Organic CompoundsAccuracyCognitive BiomarkersCognitive Impairment DetectionNeurofilament Heavy ChainNeurofilament PathologyVolatile Organic Compound BiomarkersVolatile Organic Compound DetectionVolatile Organic Compound Sensing
INTRODUCTION: We explored whether volatile organic compound (VOC) detection can serve as a screening tool to distinguish cognitive dysfunction (CD) from cognitively normal (CN) individuals. METHODS: The cognitive function of 1467 participants was assessed and their VOCs were detected. Six machine learning algorithms were conducted and the performance was determined. The plasma neurofilament light chain (NfL) was measured. RESULTS: Distinguished VOC patterns existed between CD and CN groups. The CD detection model showed good accuracy with an area under the receiver-operating characteristic curve (AUC) of 0.876. In addition, we found that 10 VOC ions showed significant differences between CD and CN individuals (p < 0.05); three VOCs were significantly related to plasma NfL (p < 0.005). Moreover, a combination of VOCs with NfL showed the best discriminating power (AUC = 0.877). DISCUSSION: Detection of VOCs from exhaled breath samples has the potential to provide a novel solution for the dilemma of CD screening.
34
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders
Carl C. Bell · JAMA · 1994 · 2.6K citations
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Akinori Nakamura, Naoki Kaneko, Victor L. Villemagne et al. · Nature · 2018 · 1.7K citations · Full text
James E. Galvin, Catherine M. Roe, Kimberly K. Powlishta et al. · Neurology · 2005 · 1.1K citations
Medicine, Neurology, Psychology +17